Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 37, Issue 4, 2014, Pages 343-349

  Ragusa, Mark ^a   Vannucci, Jacopo ^a   Ludovini, Vienna ^b   Bianconi, Fortunato ^c   Treggiari, Stefano ^d   Tofanetti, Francesca R ^b   Flacco, Antonella ^b   Colella, Renato ^c   Sidoni, Angelo ^c   Crinò, Lucio ^b   Puma, Francesco ^a  

^a Thoracic Surgery Unit   (United States)

^b Medical Oncology Division S Maria della Misericordia Hospital   (United States)

^c UNIVERSITY OF PERUGIA   (Italy)

^d SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

EGFR and KRAS mutations; Non small cell lung cancer; Prognosis

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; EXONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING; TREATMENT OUTCOME;

EID: 84905083055     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31827a7e7a     Document Type: Article

References (34)

1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of NSCLC to gefitinib. N Engl J Med. 2004; 350: 2129-2139.
2. Nicholson RI, Gee JM, ME Harper. EGFR and cancer prognosis. Eur J Cancer. 2001; 37: 9-15.
3. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003; 290: 2149-2158.
4. Pérez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with nonsmall- cell lung cancer. J Clin Oncol. 2004; 22: 323-347.
5. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353: 123-132.
6. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005; 366: 1527-1537.
7. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304: 1497-1500.
8. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361: 947-957.
9. Maemondo M, Inoue A, Kobayashi K, et al. North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362: 2380-2388.
10. Mitsudomi T, Morita S, Yatabe Y, et al. West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010; 11: 121-128.
11. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005; 23: 5900-5909.
12. Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol. 2005; 23: 8081-8092.
13. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer biological and clinical implications. Cancer Res. 2004; 64: 8919-8923.
14. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005; 97: 339-346.
15. Sugio K, Uramoto H, Ono K, et al. Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. Br J Cancer. 2006; 94: 896-903.
16. Marks JL, Broderick S, Zhou Q, et al. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol. 2008; 3: 111-116.
17. Kosaka T, Yatabe Y, Onozato R, et al. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol. 2009; 4: 22-29.
18. Graziano SL, Gamble GP, Newman NB, et al. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol. 1999; 17: 668-675.
19. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005; 2: 17.
20. Tam IY, Chung LP, Suen WS, et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res. 2006; 12: 1647-1653.
21. Ludovini V, Bianconi F, Pistola L, et al. Phosphoinositide- 3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced nonsmall cell lung cancer. J Thorac Oncol. 2011; 6: 707-715.
22. Taron M, Ichinose Y, Rosell R, et al. Activating mutations in the tyrosine kinase domain in the EGFR are associated with improved survival in Gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res. 2005; 11: 5878-5885.
23. Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2005; 92: 131-139.
24. Beasley MB, Brambilla E, Travis WD. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol. 2005; 40: 90-97.
25. Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997; 111: 1710-1717.
26. Giaccone G, Gallegos Ruiz M, Le Chevalier T, et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res. 2006; 12: 6049-6055.
27. Birim O, Kappetein AP, van Klaveren RJ, et al. Prognostic factors in non-small cell lung cancer surgery. Eur J Surg Oncol. 2006; 32: 12-23.
28. Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc. 2009; 15: 201-205.
29. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007; 98: 1817-1824.
30. Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol. 2005; 2: 3235-3242.
31. Goss GD, Lorimer I, Tsao MS, et al. A phase III randomized, doubleblind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinib in completely resected stage IBIIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19. J Clin Oncol. 2010; 28(18s): 953s, (Abstract LBA7005).
32. Sugio K, Ishida T, Yokoyama H, et al. Ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res. 1992; 52: 2903-2906.
33. Ihle NT, Byers Lauren A, Kim Edward S, et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012; 104: 228-239.
34. Kim ES, Herbst RS, Wistuba II, et al. The battle trial: personalizing therapy for lung cancer. Cancer Discov. 2011; 1: 44-53.